Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene

Isabella Ceccherini, Barbara Pasini, Furio Pacini, Maria Gullo, Italia Bongarzone, Cristina Romei, Giuseppe Santamaria, Ivana Matera, Piera Mondellini, Lucio Scopsi, Aldo Pinchera, Marco A. Pierotti, Giovanni Romeo

Research output: Contribution to journalArticle

Abstract

Somatic RET mutations have been identified in variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested. In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.

Original languageEnglish
Pages (from-to)2609-2612
Number of pages4
JournalOncogene
Volume14
Issue number21
DOIs
Publication statusPublished - 1997

Fingerprint

Proto-Oncogenes
Cysteine
Exons
Mutation
Multiple Endocrine Neoplasia Type 2b
Multiple Endocrine Neoplasia Type 2a
Nucleotides
Complementary DNA
Medullary Thyroid cancer
Neoplasms

Keywords

  • In frame deletions
  • MTC patients
  • RET proto-oncogene
  • Somatic mutations
  • Transformation assay

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. / Ceccherini, Isabella; Pasini, Barbara; Pacini, Furio; Gullo, Maria; Bongarzone, Italia; Romei, Cristina; Santamaria, Giuseppe; Matera, Ivana; Mondellini, Piera; Scopsi, Lucio; Pinchera, Aldo; Pierotti, Marco A.; Romeo, Giovanni.

In: Oncogene, Vol. 14, No. 21, 1997, p. 2609-2612.

Research output: Contribution to journalArticle

Ceccherini, I, Pasini, B, Pacini, F, Gullo, M, Bongarzone, I, Romei, C, Santamaria, G, Matera, I, Mondellini, P, Scopsi, L, Pinchera, A, Pierotti, MA & Romeo, G 1997, 'Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene', Oncogene, vol. 14, no. 21, pp. 2609-2612. https://doi.org/10.1038/sj.onc.1201079
Ceccherini, Isabella ; Pasini, Barbara ; Pacini, Furio ; Gullo, Maria ; Bongarzone, Italia ; Romei, Cristina ; Santamaria, Giuseppe ; Matera, Ivana ; Mondellini, Piera ; Scopsi, Lucio ; Pinchera, Aldo ; Pierotti, Marco A. ; Romeo, Giovanni. / Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene. In: Oncogene. 1997 ; Vol. 14, No. 21. pp. 2609-2612.
@article{03f4f8246ddf4dfca9439d0432f0ca57,
title = "Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene",
abstract = "Somatic RET mutations have been identified in variable proportion (about 30-70{\%}) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested. In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.",
keywords = "In frame deletions, MTC patients, RET proto-oncogene, Somatic mutations, Transformation assay",
author = "Isabella Ceccherini and Barbara Pasini and Furio Pacini and Maria Gullo and Italia Bongarzone and Cristina Romei and Giuseppe Santamaria and Ivana Matera and Piera Mondellini and Lucio Scopsi and Aldo Pinchera and Pierotti, {Marco A.} and Giovanni Romeo",
year = "1997",
doi = "10.1038/sj.onc.1201079",
language = "English",
volume = "14",
pages = "2609--2612",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "21",

}

TY - JOUR

T1 - Somatic in frame deletions not involving juxtamembranous cysteine residues strongly activate the RET proto-oncogene

AU - Ceccherini, Isabella

AU - Pasini, Barbara

AU - Pacini, Furio

AU - Gullo, Maria

AU - Bongarzone, Italia

AU - Romei, Cristina

AU - Santamaria, Giuseppe

AU - Matera, Ivana

AU - Mondellini, Piera

AU - Scopsi, Lucio

AU - Pinchera, Aldo

AU - Pierotti, Marco A.

AU - Romeo, Giovanni

PY - 1997

Y1 - 1997

N2 - Somatic RET mutations have been identified in variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested. In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.

AB - Somatic RET mutations have been identified in variable proportion (about 30-70%) of sporadic Medullary Thyroid Carcinoma (MTC) cases. They are represented by the Met918Thr substitution (exon 16) typical of Multiple Endocrine Neoplasia type 2B (MEN2B) and, to a lesser extent, by nucleotide changes occurring at one of five critical cysteine residues (exons 10 and 11) typical of MEN type 2A (MEN2A). An in vitro transforming activity has already been demonstrated for these mutations. A few different MTC somatic mutations have been reported so far whose biological activity has still to be tested. In this paper we report the identification, in two MTC tumor samples, of two interstitial deletions of 48 bp and 6 bp occurred in exons 10 and 11 respectively. Both were somatic heterozygous in frame mutations, not involving any cysteine residue. Moreover, the expression of a full length RET cDNA carrying one of the two deletions demonstrated a strong transforming capacity in NIH3T3 cells.

KW - In frame deletions

KW - MTC patients

KW - RET proto-oncogene

KW - Somatic mutations

KW - Transformation assay

UR - http://www.scopus.com/inward/record.url?scp=8544228324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=8544228324&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1201079

DO - 10.1038/sj.onc.1201079

M3 - Article

C2 - 9191060

AN - SCOPUS:8544228324

VL - 14

SP - 2609

EP - 2612

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 21

ER -